Belantamab Mafodotin Shows Promising Response in Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Brittany Lovely Source Type: news
More News: Cancer & Oncology | Myeloma